RE: Back down again.21 Oct 2025 23:43
The IMC site has these overview comments from earlier in the month :-
'With growing demand for model-informed drug development, biometrics, and personalized medicine, Physiomics is positioned in high-growth markets with projected double-digit CAGR across its service areas. Supported by blue-chip client relationships, increasing diversification, and a robust cash position, the Group is confident in delivering sustainable growth, enhanced profitability, and long-term shareholder value'
Lets hope PS can get some decent news out over the next week or so to restore investor confidence which is flagging a little